Roivant Sciences Ltd.
ROIVRoivant Sciences Ltd. is an American multinational healthcare company focused on applying technology to drug development and building subsidiary life sciences and health technology companies. It was founded in 2014 by Vivek Ramaswamy and is currently headed by CEO Matt Gline. Roivant maintains its headquarters in New York City as well as major offices in the biotech hubs of Boston and Basel.
Drugs in Pipeline
0
Phase 3 Programs
0
Upcoming Catalysts
2
Next Catalyst
Aug 6, 2026
TomorrowMarket Overview
Stock performance and key metrics
2 upcoming, 0 past
ROIV Earnings Report
EPS Est: $-0.45 | FQ end 2026-06
How ROIV's past catalysts played out
No drugs found in this phase.
Full breakdown — the signals behind the verdict
Frequently asked questions
When is Roivant Sciences Ltd.'s next FDA catalyst?→
Roivant Sciences Ltd.'s (ROIV) next tracked catalyst is a Earnings expected August 6, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ROIV biotech catalysts?→
Add ROIV to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Roivant Sciences Ltd.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.